ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Ashvattha Therapeutics Reports the Ability to Tune Nanomedicines to Image Neuroinflammation in Multiple Sclerosis Patients and Tumor Associated Macrophages in Cancer at SNMMI Annual Meeting

Novel nanomedicine radiotracer crosses blood brain barrier in patients with neuroinflammation

Tumor macrophage radiotracer achieves 41.6% peak tumor uptake in preclinical studies

REDWOOD CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced promising results from two novel nanomedicine radiotracers at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 21 – 24, 2025 in New Orleans.

The two agents are designed to address key gaps in neuroinflammation and cancer imaging by targeting activated microglia and macrophage, respectively.

Neuroinflammation Imaging Validation
Data presented in the poster titled "[18F]F-Flurimedrimer, a Novel Nanomedicine Radiotracer, Selectively Targeting Activated Microglia in Human Brain" showed that flurimedrimer (FMD), an investigational radiotracer engineered to selectively target activated microglia within the human brain, provided important validation of selective brain targeting. FMD is constructed from a hydroxyl dendrimer Generation 4 (HD4) with superior blood brain barrier penetration in regions of neuroinflammation compared to larger HDs (HD5 or HD6). The [18F]F-FMD was safe and well tolerated with rapid renal clearance, no tissue retention, and no brain uptake in healthy volunteers. [18F]F-FMD demonstrated selective uptake in areas of neuroinflammation in a primary progressive multiple sclerosis patient while showing no uptake in age-matched healthy volunteers, highlighting its specificity for activated microglia. These results support the agent’s potential for precise imaging of neuroinflammatory conditions.

Novel Cancer Imaging Approach
Data presented in the poster titled "A Novel Nanomedicine Radiotracer, Selectively Targeting Tumor Associated Macrophages" showed that hydroxyl dendrimers Generation 6 (HD6)-NOTA, a radiotracer with superior tumor-associated macrophage (TAM) uptake compared to other hydroxyl dendrimers of smaller size (HD4 or HD5), achieving 41.6% ID/g peak tumor uptake at 48 hours post-dose in tumor-bearing mice. TAMs are immune cells known to promote tumor growth and treatment resistance and can constitute a significant portion of tumor mass. The radiotracer successfully targeted macrophages throughout tumor structures, supporting its potential for diagnostic oncology imaging. A follow-on study using a therapeutic isotope with HD6 will be presented at a future conference.

“These results highlight the ability to tune our hydroxyl dendrimer platform to selectively target key cell populations in neurology and oncology,” said Jeff Cleland, PhD, CEO of Ashvattha Therapeutics. “FMD’s (HD4) selective brain uptake in regions of neuroinflammation demonstrates the potential to image and treat neurological diseases with neuroinflammation. For cancer, our tuned nanomedicine, HD6-NOTA, has selective TAM uptake enabling cancer imaging, and the potential to selectively kill TAMs with a therapeutic isotope. Together, they underscore our platform’s unique ability to leverage our nanomedicine for precision targeting of activated cells – without relying on traditional targeting ligands.”

About Ashvattha Therapeutics 
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, oncology, and inflammation. Ashvattha Therapeutics was founded by Kannan Rangaramanujam, Sujatha Kannan, and Jeff Cleland and incubated by Natural Capital. For more information, visit: www.avttx.com

Media
ICR Healthcare
AshvatthaPR@icrhealthcare.com

Investor Relations
Aman Patel, CFA & Adanna G. Alexander, PhD
ICR Healthcare
AshvatthaIR@icrhealthcare.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.